Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $242,000.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the sale, the director owned 6,108,287 shares of the company’s stock, valued at $29,564,109.08. This trade represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.34, for a total value of $100,200.00.
• On Tuesday, August 4th, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.25, for a total value of $97,500.00.

Recursion Pharmaceuticals Stock Up 10.4%

Shares of RXRX opened at $4.36 on Friday. The stock has a 50 day moving average price of $3.57 and a 200 day moving average price of $3.39. Recursion Pharmaceuticals, Inc. has a one year low of $2.77 and a one year high of $7.18. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.03. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -4.19 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The firm had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. During the same quarter in the previous year, the business posted ($0.41) EPS. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several research reports. Morgan Stanley set a $5.30 price objective on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $8.06.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Norges Bank acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at about $23,473,000. First Trust Advisors LP raised its stake in shares of Recursion Pharmaceuticals by 15.2% in the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock valued at $8,015,000 after acquiring an additional 344,035 shares during the period. Bank of America Corp DE raised its stake in shares of Recursion Pharmaceuticals by 18.2% in the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after acquiring an additional 384,486 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth approximately $7,370,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Recursion Pharmaceuticals by 29.3% in the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock worth $4,490,000 after acquiring an additional 331,048 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.